Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats

• Main Authors: Tanajak P., Sa-nguanmoo P., Apaijai N., Wang X., Liang G., Li X., Jiang C., Chattipakorn S., Chattipakorn N.
• 格式: 雜誌
• 出版: 2017
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85023613689&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/40215
• 機構: Chiang Mai University

© 2017 John Wiley & Sons Ltd Aims: Comparative efficacy between fibroblast growth factor 21 (FGF21) and vildagliptin on metabolic regulation, cardiac mitochondrial function, heart rate variability (HRV), and left ventricular (LV) function is not known. We hypothesized that FGF21 and vildaglipt...